U.S. biotechnology company Celgene reported a 21 percent jump in quarterly revenue, driven by demand for its key multiple myeloma drug, Revlimid.
CNBC's Meg Tirrell reports the latest earnings results for AstraZeneca, Bristol-Myers and Celgene.
Some of the names on the move ahead of the open.
In a world of disappearing market returns and negative interest rates, the search for growth has become increasingly difficult, Goldman Sachs says.
U.S. Stocks closed higher Wednesday as Wall Street celebrated better-than-expected earnings off of a record week of gains for the Dow.
The Credit Suisse research team presented its highest-conviction stock ideas in a note to clients Friday.
Check out the companies making headlines after the bell Thursday: Juno Therapeutics, GAP, BioMarin Pharmaceutical and more.
CNBC's Meg Tirrell reports the latest on the FDA putting Juno's cancer clinical trial on hold. The "Fast Money" traders weigh in on the biotech sector.
CNBC's Meg Tirrell reports on Juno Therapeutics and the news that the FDA has put one of its cancer clinical trials on hold following two deaths during the trial.
U.S. cancer drug company Medivation is discussing opening its books to Sanofi, people familiar with the matter said on Tuesday.
CNBC's Meg Tirrell discusses biotech in the bear market and what to expect going forward.
CNBC's Meg Tirrell reports on the health of the biotech sector and what could spur a turnaround in the second half of the year.
Biotech stocks rallied after a government report said that Medicare cost-cutting measures will not be triggered this year.
Jim Cramer provides his opinion on caller stocks in the Lightning Round, and opines on one of his top energy plays.
The biopharmaceutical company authorized a repurchase of up to an additional $3 billion to its shareholders.
Twitter, Celgene and Best Buy are making headlines this Wednesday morning.
Take a look at some of Wednesday's early movers: TWTR, CSCO, PG, CELG, ANF, X, BBY & more
Yana Barton, Eaton Vance Management Portfolio Manager, and Stephen DeNichilo, Federated Kaufmann Funds Portfolio Manager, discuss some of the best plays in the small-cap and large-cap spaces.
The "Fast Money" traders weighed election risks for biotech after Obama officially endorsed Hillary Clinton.
The "Fast Money" traders give you 4 trades in biotech leading up to this year's controversial election.